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The -conotoxins from fish-hunting cone snails are
potent inhibitors of voltage-gated calcium channels. The
-conotoxins MVIIA and CVID are selective N-type cal-
cium channel inhibitors with potential in the treatment
of chronic pain. The  and 2-1 auxiliary subunits in-
fluence the expression and characteristics of the 1B
subunit of N-type channels and are differentially regu-
lated in disease states, including pain. In this study, we
examined the influence of these auxiliary subunits on
the ability of the -conotoxins GVIA, MVIIA, CVID and
analogues to inhibit peripheral and central forms of the
rat N-type channels. Although the 3 subunit had little
influence on the on- and off-rates of -conotoxins, co-
expression of 2with 1B significantly reduced on-rates
and equilibrium inhibition at both the central and pe-
ripheral isoforms of the N-type channels. The 2 also
enhanced the selectivity of MVIIA, but not CVID, for the
central isoform. Similar but less pronounced trends
were also observed for N-type channels expressed in
human embryonic kidney cells. The influence of 2 was
not affected by oocyte deglycosylation. The extent of
recovery from the -conotoxin block was least for GVIA,
intermediate for MVIIA, and almost complete for CVID.
Application of a hyperpolarizing holding potential
(120 mV) did not significantly enhance the extent of
CVID recovery. Interestingly, [R10K]MVIIA and
[O10K]GVIA had greater recovery from the block,
whereas [K10R]CVID had reduced recovery from the
block, indicating that position 10 had an important influ-
ence on the extent of -conotoxin reversibility. Recovery
from CVID block was reduced in the presence of 2 in
human embryonic kidney cells and in oocytes expressing
1B-b. These results may have implications for the antino-
ciceptive properties of -conotoxins, given that the 2
subunit is up-regulated in certain pain states.
The N-type (Cav2.2) voltage-gated calcium channels play an
important role in the control of neurotransmitter release from
nerve terminals (1, 2) and are important drug targets for the
treatment of pain (3, 4) and ischemic brain injury (5). Native
N-type Ca2 channels are hetero-oligomers that comprise a
pore-forming 1 subunit (1B) and at least two auxiliary sub-
units,  and 2, which modulate the 1 subunit function (6, 7).
Two splice variants of the 1B subunit have been identified that
occur predominantly in the central (1B-d) and peripheral
(1B-b) nervous systems (8, 9). Additional splice variants that
lack large parts of the domain II-III linker region, including the
synaptic protein interaction site, have also been isolated from
human brain cDNA libraries (10). Multiple isoforms of the 
and 2 subunits also exist that can interact with the 1 subunit
to produce N-type Ca2 channels with different gating proper-
ties, allowing the fine tuning of synaptic transmissions (11).
A distinguishing feature of N-type channels is their high
sensitivity to block by -conotoxins, which are relatively small
(25 residue) polypeptides isolated from the venom of the
marine snail of the genus Conus (12, 13). -Conotoxins have
been used as research tools to help define the distribution and
physiological roles of specific N-type calcium channels (14–17)
and have potential therapeutic value as intrathecal treatments
for pain. MVIIA from Conus magus is being tested in clinical
trials as a treatment for neuropathic pain, but dose-limiting
side effects are a concern (18–20). -Conotoxin CVID from
Conus catus (21), which appears to have a wider therapeutic
window (22), is also in clinical trials (23).
The modulatory effects of auxiliary subunits on the biophys-
ical properties of Ca2 channel 1 subunits have been well
characterized. When expressed alone, 1 subunits produce
functional channels with kinetic properties that differ substan-
tially from those of the native channel (24, 25). The most
commonly observed effect of the  and 2 subunits when they
are co-expressed with the 1 subunit in a heterologous expres-
sion system such as Xenopus oocytes or HEK1 293 cells is to
increase the amplitude of macroscopic Ca2 channel currents
(typically carried by Ba2 ions) and influence the rate of chan-
nel activation and inactivation (26–29). Recently, a negative
regulatory effect of the overexpressed 3 subunit on N-type
Ca2 channel currents has been demonstrated in Xenopus
oocytes (30).
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N-type Ca2 channels are widely distributed in brain and
peripheral neurons with a variety of co-localized auxiliary
subunits (31–34). This heterogeneity in subunit composition
contributes to functional and, potentially, to pharmacological
heterogeneity. Although the pathophysiological role of auxil-
iary subunits is poorly understood, up-regulation of 2 sub-
units has been reported in association with neuropathic pain
(35–38). In a previous study, we showed that CVID was a
highly selective N-type Ca2 channel inhibitor (21) that in-
hibited nerve-evoked transmitter release at preganglionic
parasympathetic nerve terminals (15). Both CVID and
MVIIA inhibited currents mediated by the central and pe-
ripheral isoforms of the 1B subunit expressed in Xenopus
oocytes in the absence of the 2 auxiliary subunit (21). In the
present study, we show that the affinity of the -conotoxins
CVID and MVIIA to block N-type Ca2 channel current is
reduced in the presence of 2, and we identify position 10 in
-conotoxins as having an important influence on the extent
of recovery from channel block.
EXPERIMENTAL PROCEDURES
Oocyte Injection and Recording—Oocytes (stages V–VI) were surgi-
cally removed from mature Xenopus laevis frogs anesthetized by im-
mersion in 0.1% 3-aminobenzoic acid ethyl ester (MS-222). The follicu-
lar cell layer was removed by incubating oocytes in Ca2-free solution
containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES (pH
7.4) plus 2 mg/ml collagenase (Sigma type 1) for 2 h at room tempera-
ture. Oocytes were rinsed several times, sorted, and maintained at
18 °C in an ND96 storage solution that contained 96 mM NaCl, 2 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, and 5 mM pyruvate plus
50 g/ml gentamycin (pH 7.4).
cRNA was synthesized in vitro from linearized template cDNA using
an Ambion mMessage mMachine kit. cDNA encoding the rat central
1B-d and peripheral 1B-b isoforms of the N-type Ca
2 channel, as well
as the rat 3 subunit, were kindly provided by Dr. D. Lipscombe (Brown
University, Providence, RI). The rabbit 2 (2-1) subunit was a gift
from Drs. N. Klugbauer and F. Hofmann (Technology University of
Munich). Oocytes were injected with 2.5–50 ng of each subunit cRNA
using a precision injector (Drummond) as indicated under “Results.”
For co-expression studies, cRNAs encoding for the 1B, 3, and 2
subunits were injected at a 1:1:1–5 concentration ratio, respectively.
Injected cells were maintained in ND96 solution at 18 °C for 2–14 days
prior to experiments.
Electrophysiological recordings were made in a solution containing
85 mM tetraethylammonium hydroxide, 5 mM KCl, 5 mM HEPES, and
5 mM BaCl2 adjusted to pH 7.4 with methanesulfonic acid. Depolar-
ization-activated Ba2 currents were recorded using a two-electrode
voltage clamp with virtual ground circuit (GeneClamp 500B ampli-
fier; Axon Instruments Inc., Union City, CA). Voltage and current
electrodes were filled with 3 M KCl and had resistances that ranged
from 0.2–1.0 megaohms in the recording solution. Depolarization-
activated Ba2 currents were evoked from a holding potential of
either 80 mV or 120 mV by test voltages generated using pCLAMP
8.0 software and a Digidata 1200 series interface (Axon Instruments
Inc.). Membrane currents were filtered at 1–2 kHz and sampled at 10
kHz. Capacitative and leak currents were subtracted on-line using a
P/4 pulse protocol. Oocytes were continuously perfused with record-
ing solution at a flow rate of 2 ml/min at room temperature (22 °C).
Cells showing 15% change in current amplitude over a 10-min
incubation period were used in these studies to avoid problems asso-
ciated with current rundown. In an attempt to minimize the contam-
ination of recordings by Ca2-activated chloride currents, oocytes
were injected with 46 nl of 50 mM 1,2-bis(o-aminophenoxy)ethane-
N,N,N,N-tetraacetate solution at least 15 min prior to recording. All
recordings were performed in a small volume (100 l) Perspex bath.
Deglycosylation of intact Xenopus oocytes was performed for 2 h at
room temperature followed by overnight incubation at 18 °C in oocyte
media with the addition of 10 units of peptide:N-glycosidase F.
-Conotoxins were diluted in recording solution and perfused at a
flow rate of 2 ml/min. Recordings were made for at least 5 min in the
presence of each toxin until the current amplitude stabilized before
washout. For each of the -conotoxins studied, the rate of onset of
toxin block and the rate of the measurable recovery from block during
toxin washout were obtained from single exponential fits to the data
using Prism software (GraphPad). The Kd for each toxin was then
calculated using Equation 1,
Kd  Koff/Kon M (Eq. 1)
where Koff  1/off (s
1) and Kon  (1/on  Koff)/[toxin] (M
1s1).
HEK Cell Expression and Electrophysiology—HEK tsA201 cells were
maintained at 37 °C (5% CO2) in Dulbecco’s modified Eagle’s medium
supplemented with fetal bovine serum, penicillin, and streptomycin
(Invitrogen). Cells were split to 10% confluence with trypsin-EDTA and
transfected 12 h later with cDNAs encoding 1B (25), 1b, or 3 and
green fluorescent protein with or without 2 using a standard calcium
phosphate protocol. Cells were moved to 28 °C 24 h after transfection
and maintained for up to 7 days. Cells were transferred into 20 mM
barium external solution containing 20 mM BaCl2, 1 mM MgCl2, 10 mM
HEPES, 40 mM tetraethylammonium chloride, 10 mM glucose, and 65
mM CsCl (pH 7.2) and recorded at room temperature (22 °C). Boro-
silicate glass pipettes of 3-megaohm resistance were filled with a
cesium methane sulfonate-based internal solution containing 109 mM
CsCH3SO4, 4 mM MgCl2, 9 mM EGTA, and 9 mM HEPES (pH 7.2). Data
were acquired and filtered at 1 kHz with an Axopatch 200B amplifier
and pCLAMP 8.0 software (Axon Instruments Inc.). Series resistance
was compensated to 90%. Membrane currents were evoked every 15 s
by 150-ms test pulses from 100 mV to 10 or 20 mV. Cells were
perfused directly with control or toxin-containing bath solutions via a
custom-built perfusion system allowing complete solution changes in
1 s. Data were leak-subtracted and analyzed with Clampfit 8.0 (Axon
Instruments Inc.), and graphed in SigmaPlot 2000 (SPSS Inc.).
Peptide Synthesis—The -conotoxins CVID, [K10R]CVID, MVIIA,
[R10K]MVIIA, GVIA, and [O10K]GVIA (see Fig. 1) were assembled
manually using t-butoxycarbonyl chemistry in situ neutralization solid-
phase peptide synthesis (39), deprotected, cleaved, and purified as
described previously (40). The purified reduced peptides were oxidized
in aqueous 0.33 M NH4Oac and 0.5 M guanidine-HCl (pH 7.8) for 2–4
days at 4 °C in the presence of reduced and oxidized glutathione (molar
ratio 1:100:10). Oxidized peptides were purified by preparative reversed
phase high pressure liquid chromatography (40). Mass spectra were
measured on a time-of-flight mass spectrometer (PerSeptive Biosys-
tems) equipped with an electrospray atmospheric pressureionization
source.
Radioligand Binding Assays—-Conotoxin displacement of 125I-
GVIA from rat brain membrane was performed as described previously
(41). Data are from at least three experiments, each performed
in triplicate.
1H NMR Spectroscopy—All NMR spectra were recorded on a Bruker
ARX 500 spectrometer equipped with a z-gradient unit or on a Bruker
DMX 750 spectrometer equipped with a x,y,z-gradient unit. Peptide
concentrations were 2 mM. H chemical shifts were obtained from
spectra of CVID, [K10R]CVID, MVIIA, [R10K]MVIIA, GVIA, and
[O10K]GVIA in 95% H2O and 5% D2O (pH 3.5) at 293 K. Restraints
used for the three-dimensional structure calculations of [R10K]MVIIA,
GVIA and [O10K]GVIA were from spectra recorded at 275 and 293 K.
Three-dimensional solution structures were calculated using the tor-
sion angle dynamics/simulated annealing protocol in XPLOR version
3.851, as described previously (41).
RESULTS
Effects of 3 and 2 Subunits on the Biophysical Properties
of N-type Ca2 Channels Expressed in Oocytes—Depolariza-
tion-activated Ba2 currents were recorded in Xenopus oocytes
FIG. 1. Amino acid sequence alignment of the -conotoxins
CVID (from C. catus), MVIIA (C. magus), and GVIA (C. geogra-
phus) and the analogues [K10R]CVID, [R10K]MVIIA, and
[O10K]GVIA. Shown are the positions of the four loops and the disul-
fide connectivity that characterize -conotoxins. Position 10 residues
are boxed.
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3–5 days following the injection of 2.5 ng of cRNA encoding for
the 1B-d (central isoform) of the N-type Ca
2 channel (Fig. 2).
Currents evoked by 150-ms voltage steps to 0 mV from a
holding potential of 80 mV typically ranged from 150–500 nA
in peak current amplitude (Fig. 2A). Co-expression of the 3
subunit at a 1:1 ratio with 1B-d increased the peak current of
current-voltage (I-V) relationships 2-fold compared with 1B-d
expressed without the addition of recombinant 3. In agree-
ment with a previous report (8), 3 had only minor effects on
the activation and inactivation kinetics of Ca2 channel cur-
rent (Fig. 2A). Co-expression of the 3 subunit caused a signif-
icant (p  0.001) hyperpolarizing shift in the half-maximal
activation voltage (V1⁄2) from 2.6 	 0.8 (n  11) for 1B-d alone
to 8.3 	 0.8 (n  16) in the presence of 3 (Fig. 2, B and C).
Co-expression of the 1B-d and 3 subunits together with the
2 subunit resulted in an additional enhancement of the peak
current amplitude (Fig. 2, A and B). On average, the peak
current amplitude from the I-V curve obtained in the presence
of the 2 subunit was 2-fold larger than that obtained with the
1B-d  3 subunit combination alone. Ca
2 channel currents
recorded from oocytes expressing 2 also exhibited faster ac-
tivation and inactivation kinetics during the 150-ms test pulse
(Fig. 2A). Co-expression of 2  3 caused a small but signif-
icant (p  0.01) depolarizing shift of V1⁄2 for 1B-d activation to
5.2 	 0.6 mV (n  16) compared with 3 alone (8.3 	 0.8
mV) (Fig. 2, B and C). A similar 2-induced depolarizing shift
of I-V curves has been reported for N- and R-type Ca2 chan-
nels (29, 42). The 1B-b (peripheral isoform) channel current
amplitude and channel properties were also modulated by 3
and 2 subunits in a manner similar to their influence
on 1B-d.
Effect of 3 and 2 Subunits on the Inhibition by -Cono-
toxins of N-type Ca2 Channel Current Expressed in Oo-
cytes—To assess the influence of different auxiliary subunits on
the pharmacology of -conotoxins at N-type Ca2 channels, we
compared the ability of the -conotoxins CVID and MVIIA and
FIG. 2. The effect of auxiliary subunits on the biophysical
properties of the N-type Ca2 channel 1B subunit. A, represent-
ative inward Ba2 currents recorded in Xenopus oocytes expressing the
1B-d subunit alone or in combination with the 3 and 2 subunits. The
broken line indicates the zero current level. Currents were evoked by
150-ms voltage steps to 0 mV from a holding potential of 80 mV.
Residual capacitive transients after leak subtraction have been erased
for clarity. B, effect of the 3 and 2 subunits on I-V relationship for
1B-d (n  11–16 oocytes from 2–3 batches of oocytes). C, effect of the 3
and 2 subunits on the voltage dependence of 1B-d activation. Data
were derived from the I-V relationships obtained in B. Error bars
show S.E.
FIG. 3. Development and recovery from CVID block of N-type
channels. A, sequential block of inward Ba2 currents recorded in a
Xenopus oocyte expressing the peripheral (1B-b) isoform of the N-type
channel in combination with the 3 subunit. Currents were evoked by
200-ms voltage steps to 0 mV from a holding potential of 80 mV. Toxin
was added just prior to the first trace (control). B, currents recorded in
the same oocyte during toxin washout. For A and B, current records
were obtained at 15-s intervals but are shown at 30-s intervals for
clarity, and broken lines indicate the zero current level. C, normalized
peak current amplitude as a function of time obtained from the traces
shown in A and B. The period of exposure to 1 nM CVID is indicated by
the solid bar. Solid lines are the single exponential fits to the data used
to obtain the on- and off-rates. The extent and recovery from block were
obtained from these curve fits.
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the analogs [K10R]CVID and [R10K]MVIIA (see Fig. 1) to
inhibit N-type currents mediated by either 1B alone, 1B  3,
or 1B  3  2. On- and off-rates of channel block and
estimates of potency (Kd) for the different Ca
2 channel sub-
unit combinations were obtained following application and
washout of each toxin (Fig. 3, A and B). In all cases, the current
decrease attributed to toxin block reached a steady state and
was fitted by a single exponential function. A single exponential
function also fitted recovery from block during toxin washout
(Fig. 3C). The kinetics, extent, and recovery from block were
determined for each toxin from curve fits. Data obtained for the
peripheral (1B-b) and central (1B-d) isoforms of the N-type Ca
2
channel are presented in Tables I and II, respectively.
For the 1B subunit expressed alone or in combination with
the 3 subunit, the addition of 1 nM CVID or MVIIA inhibited
a substantial portion of the Ba2 current mediated by either
the peripheral or the central isoform of the N-type Ca2 chan-
nel (Tables I and II). CVID was less potent than MVIIA, espe-
cially at the 1B-d subunit (Tables I and II; Fig. 4A). The
analogues [K10R]CVID and [R10K] MVIIA had similar profiles
of inhibition of 1B to CVID and MVIIA, respectively.
Co-expression of the 2 subunit with 1B  3 subunit
dramatically reduced the apparent affinity of the N-type Ca2
channel for the -conotoxins (Figs. 4 and 5), ranging from
150–680-fold at 1B-b to 80–220-fold at 1B-d (Tables I and II).
At both splice variants, the effect of 2was most prominent for
[K10R]CVID and CVID compared with MVIIA and
[R10K]MVIIA. The reduction in potency induced by 2 arose
from a markedly reduced on-rate for these -conotoxins with-
out any significant effect on off-rate kinetics (Tables I and II;
Fig. 5). The same influence of 2 on the kinetics and potency
of -conotoxin block at 1B were also observed in the absence of
the added 3 (Table III). Similar estimates of potency (log IC50)
were obtained using equilibrium concentration-response data
obtained for -conotoxins CVID (9.93 	 0.03, 7.66 	 0.03)
and MVIIA (10.19 	 0.07, 8.30 	 0.03) inhibition of 1B-d 
3 in the absence or presence of 2, respectively (Fig. 4B).
Two batches of oocytes expressing 1B-d  3 were found to
be particularly sensitive to MVIIA block (Fig. 4B, diamonds);
this sensitivity was pronounced when the oocytes were main-
tained longer and was similar to results obtained previously for
CVID at 1B-d alone (21), indicating that the picomolar inhibi-
tion occasionally observed is an oocyte batch-dependent phe-
nomena. Interestingly, a plot of on as a function of -conotoxin
concentration gives a linear relationship with a slope 
1.
This difference was most pronounced for on obtained in the
absence of 2 (0.48 	 0.03) but still significantly different
from unity in the presence of 2 (0.73 	 0.01). Assuming
constant off-rate kinetics, this change in the on-rate gives rise
to different potency estimates, depending on the concentration
of -conotoxin tested. In the absence of 2, at 0.1 nM CVID, the
estimated Kd was 0.06 nM, whereas at 10 nM CVID the esti-
mated Kd was 20-fold greater (1.3 nM), suggestive of channel
heterogeneity.
Reversibility of -Conotoxin Inhibition of N-type Ca2 Chan-
nel Current Expressed in Oocytes—As observed previously for
MVIIA (43, 44), recovery from block (reversibility) for MVIIA
and CVID was found to be incomplete (Fig. 6; Tables I and II).
For 1B-b expressed alone, recovery from block was less (45%)
for toxins with Arg at position 10 compared with those with a
Lys at position 10 ( 85%). For 1B-d channels expressed alone
(Table II), CVID and [K10R]CVID had similar levels of recov-
ery (45%), whereas [R10K]MVIIA (83%) had enhanced recov-
ery compared with MVIIA (25%). For 1B-b  3 channels,
recovery from block was also greater for peptides containing
Arg at position 10, and for 1B-d  3 channels it was greater
for [R10K]MVIIA. Co-expression of 2 with 1B-b  3 further
reduced recovery from block for CVID and [K10R]CVID but not
for MVIIA and [R10K]MVIIA (Fig. 6, Tables I and II). In
contrast, for 1B-d  3  2 channels the recovery from block
was significantly reduced for MVIIA and [R10K]MVIIA but not
for CVID and [K10R]CVID. Overall, recovery was least for
MVIIA (13%) at 1B-d and greatest for [R10K]MVIIA at 1B-b
(85%). Previous studies have suggested that the extent of re-
covery from -conotoxin block is enhanced at hyperpolarizing
holding potentials (45). In the present study, applying a hyper-
polarizing holding potential was found to have no significant
influence on the extent of recovery from block, at least for CVID
(Table III).
GVIA has a sequence that is distinct from those of other
-conotoxins (see Fig. 1) and shows pseudo-irreversible binding
to the N-type Ca2 channel (45). On the basis that position 10
was found to influence the reversibility of MVIIA and CVID
inhibition of N-type calcium channels, we synthesized the an-
alogue [O10K]GVIA to investigate the importance of position
10 for GVIA reversibility. Interestingly, this analogue also
showed enhanced reversibility compared with GVIA (Fig. 6, B
and C), suggesting that an interaction between the toxin resi-
due at position 10 and the N-type calcium channel is a key
determinant in stabilizing the toxin-bound state.
-Conotoxin CVID Inhibition of N-type Ca2 Channel Cur-
rent Expressed in tsA201 Cells—In contrast to the results ob-
TABLE I
Kinetics and extent of block by the -conotoxins CVID, MVIIA, and analogues on the peripheral (1B-b) N-type Ca
2 channel expressed in
Xenopus oocytes alone or in combination with 3 and 2 subunits
-Conotoxins were applied at 1 nM (1B-b, 1B-b  3) or at 100 nM (1B-b  3  2). The extent of recovery from block was determined as
described in Fig. 3. Averaged data 	 S.E. (n  5–10 oocytes, as indicated).
Toxin Amount Subunits Kon Koff Kd Inhibition Recovery No.
nM M1s1  107 s1  103 nM % %
CVID 1 B-b 0.8 	 0.1 4.3 	 0.8 0.58 	 0.11 40 	 2 86.9 	 7.3 5–7
1 B-b  3 1.4 	 0.2 3.7 	 0.5 0.3 	 0.06 87.5 	 3 65.7 	 8.7 7–8
100 B-b  3  2 3 	 0.6 (10
4) 3.5 	 0.7 78 	 17.2 88 	 5 36.1 	 5.6 6
K10RCVID 1 B-b 2.8 	 0.5 5.2 	 0.8 0.18 	 0.04 69.7 	 2.6 45 	 3.9 8
1 B-b  3 1.5 	 0.1 2.9 	 0.3 0.18 	 0.02 85 	 1.9 43.7 	 5.8 5–9
100 B-b  3  2 2 	 0.3 (10
4) 3 	 0.7 124 	 29 91.1 	 4.6 28.7 	 3.6 5–6
MVIIA 1 B-b 4.2 	 0.4 3 	 1.2 0.2 	 0.02 65.9 	 5.7 40.5 	 5.2 7
1 B-b  3 3.5 	 0.6 4.9 	 0.4 0.12 	 0.02 85.3 	 4 41.9 	 6.1 10
100 B-b  3  2 1.8 	 0.2 (10
5) 2.1 	 0.3 18.6 	 3.8 97.5 	 0.6 38.3 	 3.8 5–9
R10KMVIIA 1 B-b 4.3 	 0.6 10.7 	 1.6 0.24 	 0.05 69.5 	 4.3 83.9 	 7.1 6–8
1 B-b  3 4.2 	 0.5 4.3 	 0.4 0.11 	 0.02 72.9 	 6.5 96.2 	 4.9 6–8
100 B-b  3  2 1.2 	 0.1 (10
5) 1.8 	 0.3 15.6 	 2.6 96 	 0.3 85.1 	 16 6
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tained when 1B  3 was expressed in oocytes where 50%
current inhibition was obtained using 0.1–1 nM CV1D, higher
concentrations (100 nM) of CVID were required to inhibit
Ba2 currents through 1B  1b expressed in tsA201 cells
(Fig. 7). This reduced potency may be due in part to the differ-
ential effects of the 1b and 3 subunits on conotoxin potency
or to the higher external Ba2 concentration used as the charge
carried in these experiments, which can influence the affinity
of -conotoxins (for example, compare Refs. 43 and 48). Similar
differences in potency between the two expression systems
were also observed for MVIIA (data not shown). Consistent
with the results obtained in oocytes, coexpression of the 2
subunit reduced CVID affinity, but to a lesser extent (Fig. 7, A
and B). Washout of CVID was again incomplete, especially in
the presence of the 2 subunit (Fig. 7C).
Radioligand Binding Results—Potencies (pIC50) to displace
125I-GVIA from rat brain membrane were determined to estab-
lish whether position 10 changes the affected affinity for native
N-type channels found centrally (Table IV). These results
showed that the mutated -conotoxins had a potency similar to
that of their native counterparts at brain N-type calcium
channels.
1H NMR and Three-dimensional Structure Calculations—To
further probe the role of residue 10 in affinity to oocyte-ex-
pressed 1B,
1H NMR was used to identify any structural
changes that may be associated with this residue replacement.
Comparing H chemical shifts with random coil values for a
series of related peptides is a sensitive method for identifying
changes introduced in the peptide backbone. Replacing residue
10 in MVIIA and GVIA with the corresponding Lys residue
from CVID introduced minor changes in the secondary H
chemical shift in [R10K]MVIIA across residues 10–14, whereas
the changes in the secondary H chemical shift in [O10K]GVIA
were larger in magnitude and spread across residues 8–14.
Replacing Lys-10 in CVID with an Arg residue did not result
in alterations of the secondary H chemical shift (15). Three-
dimensional solution structures were calculated for
[R10K]MVIIA and [O10K]GVIA, which showed significant sec-
ondary H chemical shift changes from their native counter-
parts. Analysis of these structures revealed that replacing
Arg-10 in MVIIA with the similar Lys residue did not alter the
overall three-dimensional structure of the peptide (Fig. 8B),
which is consistent with the relatively small changes in the
secondary H chemical shift observed (Fig. 8A). For
[O10K]GVIA, which showed larger H chemical shift changes,
the Hyp to Lys replacement resulted in destabilization of loop
2 residues 9–14 as compared with GVIA. The remainder of the
[O10K]GVIA peptide backbone, however, was not perturbed by
the Hyp to Lys residue substitution and retained a similar
overall structure to GVIA (Fig. 8B).
DISCUSSION
The biophysical effects of auxiliary  and 2 subunits on the
pore-forming 1 subunit of calcium channels have been well
documented (26, 28, 29, 42). The aim of the present study was
to determine how these auxiliary subunits influence the po-
TABLE II
Kinetics and extent of block by the -conotoxins CVID, MVIIA, and their analogues on the central (1B-d) N-type Ca
2 channel expressed in
Xenopus oocytes alone or in combination with 3 and 2 subunits
-Conotoxins were applied at 1 nM (1B-d, and 1B-d  3) or at 100 nM (1B-d  3  2). The extent of recovery from block was determined as
described in Fig. 3. Averaged data 	 S.E. (n  5–8, as indicated).
Toxin Amount Subunits Kon Koff Kd Inhibition Recovery No.
nM M1s1  107 s1  103 nM % %
CVID 1 B-d 1.3 	 0.3 14.6 	 2 1.2 	 0.2 45 	 5 43 	 6.4 5
1 B-d  3 1.2 	 0.1 3.7 	 0.1 0.31 	 0.04 83.7 	 7.7 40.5 	 2.4 8
100 B-d  3  2 4.5 	 1.5 (10
4) 2.71 	 0.6 48 	 17 93 	 3.3 33.6 	 6.9 7
K10RCVID 1 -d 1.6 	 0.2 2.7 	 0.3 0.19 	 0.05 78.1 	 6.6 49.2 	 15 5
1 -d  3 1.5 	 0.3 2.2 	 .06 0.18 	 0.04 87.4 	 2 42.7 	 10 5
100 B-d  3  2 4.6 	 0.27 (10
4) 1.8 	 .2 39.5 	 6.3 97.3 	 3.6 54.4 	 4.5 6
MVIIA 1 -d 6 	 0.8 2.4 	 0.4 0.04 	 0.01 73.4 	 3.9 25.3 	 2.1 5
1 B-d  3 6.3 	 0.8 4.9 	 1.1 0.07 	 0.02 89.7 	 2.1 46.3 	 7.6 5–7
100 B-d  3  2 2.5 	 0.2 (10
5) 2.6 	 1.3 5.7 	 0.73 96 	 0.8 13.2 	 2.6 5
R10KMVIIA 1 B-d 4.7 	 0.6 8.6 	 1.1 0.16 	 0.02 88.5 	 4.5 82.7 	 5.9 6
1 B-d  3 5.8 	 0.9 5.5 	 0.8 0.09 	 0.01 88.7 	 4.6 87 	 4.9 6
100 B-d  3  2 1.6 	 0.2 (10
5) 1.4 	 0.3 8.9 	 2.2 93.9 	 0.8 47.8 	 9.7 5
FIG. 4. Potency of -conotoxins at 1B expressed in the pres-
ence or absence of 3 and 2. A, potency estimates (Kd) obtained
from kinetic data in Tables I and II. B, potency estimates obtained from
concentration-response curves at 1B-d (n  4–8 using six batches of
oocytes) produced similar results. Current inhibition for 1B-d  3 or
1B-d  3  2 was evaluated at 7 or 10 min after starting toxin
perfusion, respectively (see Fig. 5). Data indicated by the diamonds are
from two batches of oocytes showing an unusually high sensitivity of
1B-d  3 to the block by -conotoxin MVIIA (n  4–7). Error bars
show S.E.
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tency of -conotoxins to inhibit currents mediated by N-type
(Cav2.2) calcium channels. Expression of the peripheral (1B-b)
and central (1B-d) isoforms in Xenopus oocytes yielded Ca
2
channel currents that were enhanced 2-fold upon co-expression
with the 3 subunit. However, the 3 subunit had no signifi-
cant effect on the ability of the -conotoxins CVID, MVIIA, and
their analogues to inhibit currents mediated by the 1B sub-
unit. In general, the central 1B-d isoform was more sensitive to
block than the peripheral 1B-b isoform for all -conotoxins
studied, although the maximum difference observed was
5-fold.
In addition to further enhancing the peak current ampli-
tudes of both the central and peripheral isoforms of the N-type
Ca2 channel and shifting the V1⁄2 for activation as observed
previously (29), the 2 subunit dramatically reduced -cono-
toxin affinity for N-type channels expressed in oocytes. Co-
expression of the 2 subunit together with 1B  3 subunits
caused a 100-fold decrease in the sensitivity of the channel to
block by CVID, MVIIA, and analogues. Kd values obtained for
the inhibition of N-type currents by -conotoxin MVIIA in the
presence of the 2 subunit were similar to values reported
previously (44, 46, 47). The 2 subunit caused a decrease in
toxin sensitivity at both the peripheral and central isoforms of
the N-type Ca2 channel. In the presence of 2, selectivity for
the central over the peripheral isoform was MVIIA 
[K10R]CVID 
 [R10K]MVIIA  CVID (Fig. 4A; Tables I and
II), indicating that Arg at position 10 contributes to central
selectivity. Consistent with the results obtained in Xenopus
FIG. 5. Co-expression of 2 decreases the affinity of -conotoxins for N-type channels. A and B, representative inward Ba
2 currents
recorded from Xenopus oocytes expressing the central isoform (1B-d) in combination with either the 3 subunit (A) or the 3  2 subunits (B)
during a 7- or 10-min application of 10 nM CVID, respectively. Currents were evoked by voltage steps to 0 mV from a holding potential of 80 mV
every 20 s. CVID at 10 nM showed robust inhibition of currents through the 1B-d  3 channel but had little effect on the 1B-d  3  2
combination. C and D, normalized average peak current amplitude is shown as a function of time obtained from oocytes expressing 1B-d  3 (C)
or 1B-d  3  2 (D) exposed to different concentrations of CVID. E, a plot of the initial on-rate on versus CVID concentration is fitted by linear
relationships. Error bars show S.E. (n  4–8 for each data point using six batches of oocytes).
Auxiliary Subunit Influences on -Conotoxin Pharmacology34710
 at UQ Library on September 2, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
oocytes, the 2 subunit also decreased the -conotoxin CVID
sensitivity of 1B channels expressed in HEK tsA201 cells,
although the effect was not as dramatic. This result agrees
with an earlier observation in HEK cells in which 2 de-
creased the affinity to GVIA 3-fold (48).
Our results demonstrate that the decrease in affinity caused
by 2 was achieved through a slowing of the -conotoxin
association rate (kon). It is possible that this effect may arise
from electrostatic shielding or repulsion, perhaps through the
proximity of the bulky and heavily glycosylated extracellular 2
domain to the -conotoxin binding site, which presumably re-
sides in the outer vestibule of the channel pore (47). Indeed,
oocytes may uniquely glycosylate membrane proteins, thus
accounting perhaps for the differences observed between the
two expression systems used here. However, the effect of the
2 on -conotoxin pharmacology was not influenced by oocyte
deglycosylation (Table III). If the effects were indeed due in
part to an 2 subunit-induced masking of surface charges,
then recording in 20 mM Ba2 would be expected to attenuate
any 2 effects due to the increased charge-screening capability
of 20 mM Ba2. Unfortunately, we were unable to directly test
this possibility, because currents from 1B expressed in HEK
cells in the absence of 2 were too small to measure by using
5 mM Ba2 as the charge carrier. A direct physical restriction of
-conotoxin’s access to its binding site on the N-type Ca2
channel protein seems unlikely, as this would be expected to
slow both the association and dissociation rates. In contrast,
Felix et al. (49) reported that the binding of [3H]PN200–110 to
the cardiac L-type (1C) channel was increased by the 2 moiety
of 2, presumably by affecting the conformation of the 1C
subunit. It is therefore possible that the opposite effect occurs
at 1B. In addition to decreasing conotoxin sensitivity, coex-
pression of the 2 subunit reduced the percentage of current
recovery from conotoxin block following washout. Surprisingly,
this effect appeared to be specific to both the 1B isoform
expressed and to the type of toxin used, with the effect being
greatest for CVID analogues in cells expressing the peripheral
isoform and for MVIIA analogues in cells expressing the cen-
tral isoform. The reason for this difference in the 2 effect on
toxin recovery between 1B isoform is not clear. The effects of
2 on -conotoxin affinity appears to be unrelated to gabap-
entin action, because application of gabapentin (100 M) failed
to produce any immediate inhibition of 1B-d  2  3 cur-
rent expressed in oocytes.2
It was previously reported that the sensitivity of 1B-d to
CVID block was two orders of magnitude greater when ex-
pressed in the absence of the 3 subunit (21). In the present
study, however, only occasional batches of oocytes expressing
1B-d alone had high -conotoxin affinity (20-fold enhanced;
see Fig. 4B); in this instance, the affinity was for MVIIA.
Apparently, low picomolar affinity is not restricted to CVID
and presumably arises from heterogeneity in 1B pharmacology
in oocytes, perhaps as a result of post-translational processing
2 T. Yasuda, D. J Adams, and R. J. Lewis, unpublished observations.
TABLE III
Kinetics and extent of block by -conotoxin CVID at 1B-d 	 3 at different holding potentials (HP) and after
peptide  N-glycosidase F (PNGase F; 10 units) treatment (53)
The extent of recovery from block was determined as described in Fig. 3. Averaged data 	 S.E. (n  4–7 oocytes, as indicated).
Toxin Subunits HP Kon Koff Kd Inhibition Recovery No.
nM mV M1s1  104 s1  103 nM % %
1 B-d 80 1.37 	 0.09 0.72 	 0.07 0.052 	 0.004 62.6 	 6.9 77 	 11.4 6
1 B-d 120 1.33 	 0.08 0.76 	 0.14 0.057 	 0.01 47.9 	 6 90 	 6.5 5
100 B-d  2 80 3.33 	 0.29 0.62 	 0.10 21.1 	 5.2 89 	 1.1 19.6 	 3.9 7
100 B-d  2 120 2.71 	 0.34 0.41 	 0.47 16.7 	 3.6 84.4 	 2.5 31 	 6.5 5
100 B-d  2  PNGase F 80 3.49 	 0.16 0.60 	 0.13 17.5 	 4.2 87.2 	 1.3 19.1 	 3.6 4
FIG. 6. Position 10 influences the reversibility of the N-type
channel block by-conotoxins. A and B, normalized peak 1B-b  3
current amplitude as a function of time for 1 nM MVIIA and
[R10K]MVIIA (A) and 1 nM GVIA and [O10K]GVIA (B). C, the average
recovery of current amplitude following washout of -conotoxins.
Shown are data obtained from oocytes expressing the 1B-b subunit
alone (solid bars) or in combination with either the 3 subunit (hatched
bars) or 3  2 subunits (open bars). Error bars show S.E. (n  5).
Auxiliary Subunit Influences on -Conotoxin Pharmacology 34711
 at UQ Library on September 2, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
or auxiliary protein heterogeneity. Similar potency differences
were also obtained when Kd estimates at 1B-d expressed alone
were calculated using on-rates of block determined at different
concentrations of CVID, which is again suggestive of heteroge-
neity in 1B pharmacology in oocytes.
In addition to the effect of auxiliary subunits on toxin po-
tency, an overall difference in the extent of recovery from block
by different -conotoxins was also observed. Recovery from
block by CVID was greater than that for MVIIA, whereas GVIA
block was virtually irreversible. Interestingly, CVID reversibil-
ity was reduced for the peripheral form of the N-type channel in
the presence of 2, whereas MVIIA reversibility was reduced
at the central form in the presence of 2. In the spinal cord,
this difference may allow CVID to preferentially inhibit the
ascending presynaptic transmission presumably driven by pe-
ripheral subtypes and permit MVIIA to preferentially inhibit
the postsynaptic and descending presynaptic transmission pre-
sumably driven by central subtypes. A 3-fold preference for the
central isoform displayed by MVIIA (but not CVID) is expected
to further increase such central selectivity. Central versus pe-
FIG. 7. -Conotoxin block of N-type (1B  1b) channel cur-
rents transiently expressed in HEK tsA201 cells in the absence
or presence of 2. A and B, -conotoxin CVID inhibition of N-type
channels is reduced by the calcium channel 2 subunit. Representative
current traces recorded in 20 mM Ba2 external solution depict N-type
current block by 100 nM CVID in the presence or absence of 2. Scale
bar labels correspond to both sets of traces; note different scale bar
sizes. Data are plotted as mean 	 S.E.; numbers in parentheses indicate
number of experiments. Asterisks indicate p  0.05 in unpaired t-tests.
C, time courses illustrate current reduction by 3 M CVID (b) and
recovery during washout (gray triangles, 2; black squares, 2)
with 20 mM Ba2 external solution (a). Inset shows that the percentage
of current recovery from CVID block after 2 min of washing is greater
in cells lacking the 2 subunit (black) than in 2-expressing
cells (gray).
TABLE IV
Potency to displace 125I-GVIA from rat brain membranes
-Conotoxin Potency (pIC50) 95% CI
a
M
CVID 10.42 10.32–10.52
K10RCVID 10.24 10.14–10.33
MVIIA 10.71 10.66–10.77
R10KMVIIA 10.60 10.50–10.70
GVIA 10.55 10.45–10.63
O10KGVIA 10.73 10.64–10.82
a Confidence interval.
FIG. 8. 1H NMR studies. A, H chemical shift for the three residue
10-substituted -conotoxins and their native counterparts. B, three-
dimensional solution structures of MVIIA (accession number
RCSB022889; Protein Data Bank (PDB) code 1TTK) (15), [R10K]MVIIA
(accession number RCSB02280; PDB code 1TT3) (15), GVIA (accession
number RCSB0228890; PDB code 1TTL), and [O10K]GVIA (accession
number RCSB022862; PDB code 1TR6). Superimposition of the 20
lowest energy conformations across the entire backbone are shown with
the exception of [O10K]GVIA, which was superimposed over residues
1–9 and 15–27.
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ripheral selectivity may have relevance to pain management,
given that a dorsal root ganglion-specific splice variant of the
N-type calcium channel has recently been identified in periph-
eral pain pathways (50). It is possible that the selectivity of
MVIIA for central isoforms of the N-type calcium channel may
explain why it has a narrower therapeutic window than CVID
in rat models of inflammatory (22) and neuropathic pain (51).
In an attempt to identify which residues on -conotoxins
influence reversibility, we investigated a number of position 10
mutants that had previously been identified as influencing
calcium channel selectivity (15). [R10K]MVIIA had enhanced
reversibility as compared with MVIIA for both the central and
peripheral isoforms of the N-type Ca2 channel. Relative to
CVID, [K10R]CVID had diminished reversibility at the periph-
eral isoform of the N-type Ca2 channel or little influence at
the central isoform. The influence of position 10 on toxin re-
versibility was extended to GVIA, with [O10K]GVIA showing
enhanced recovery. Taken together, these results suggest that
position 10 is a key determinant of -conotoxin reversibility.
This effect appears to take place through a specific interaction
between residue 10 of the toxin and another residue on the
N-type Ca2 channel protein, because the shape of the toxin is
little altered but apparently more flexible in the mutants.
Regions of the a1B subunit crucial for the binding of GVIA in
the external vestibule of the channel (domain III; S5-S6 region)
have been identified (52). In a recent study by Feng et al. (47),
residue Gly-1326 was found to be a major determinant of GVIA
and MVIIA binding, as mutation of this residue to a proline
rendered a block by these -conotoxins fully reversible. In
contrast to the 2 subunit, which affected the -conotoxin
on-rate, position 10 residues had a significant impact on the
extent of reversibility of -conotoxins, irrespective of the aux-
iliary subunit present.
Replacement of Lys10 in -conotoxins CVID with Arg-10 did
not alter the secondary H chemical shifts compared with the
parent peptides. In [R10K]MVIIA, the small change in second-
ary H chemical shifts across residues 9–14 did not influence
the overall three-dimensional structure as compared with
MVIIA. In comparison, replacing the Hyp-10 in GVIA with a
Lys destabilized the loop 2 of GVIA. This suggests that remov-
ing the ring-constrained Hyp residue removes an important
stabilizing interaction within the peptide. The fact that the
results of the washout studies showed that this residue replace-
ment in GVIA increased the reversibility of the peptide sug-
gests that GVIA binds to the N-type calcium channel differ-
ently than to CVID and MVIIA. This was supported by
radioligand binding studies that show no change in binding
affinity for [O10K]GVIA to the N-type channels in rat brain as
compared with GVIA. Thus, the shape of loop 2 in GVIA clearly
has effects on reversibility but not on the displacement of
125I-GVIA from rat brain membrane. This change in reversibil-
ity could be due to a loss of strong interactions between resi-
dues in loop 2 and the channel following the destabilization of
loop 2 in [O10K]GVIA. However, changes observed in the re-
covery from block by MVIIA are more likely due to changes in
the side chain properties introduced by the Arg to Lys substi-
tution, because CVID and [R10K]MVIIA show greater revers-
ibility as compared with [K10R]CVID and MVIIA. Again, there
is no difference among these different peptides in their abilities
to displace 125I-GVIA from rat brain membrane. These results
support the idea that GVIA interacts with the N-type channels
through a different pharmacophore as compared with MVIIA
and CVID (13).
In summary, we report that the 2 subunit dramatically
decreases the sensitivity of N-type calcium channels to block by
-conotoxins in oocytes, with qualitatively similar results ob-
served for 1B expressed in HEK cells. Furthermore, the recov-
ery from block by the -conotoxins MVIIA and GVIA is partly
dependent on the nature of the residue at position 10, providing
a means to manipulate dissociation kinetics. Given that the 2
subunit is up-regulated in animal models of neuropathic pain
(37), differences in potency and recovery from block may influ-
ence how effectively -conotoxins reverse different painful con-
ditions in vivo.
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